Clinical Trials Browser

Phase 2 × Carcinoma, Transitional Cell × sapanisertib × Clear all

NCT03047213 2026-03-18

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Phase 2 Active not recruiting

17 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03745911 2018-11-19

Paclitaxel and TAK-228 in Urothelial Carcinoma

Phase 2 Unknown

Carcinoma, Transitional Cell